Huang et al., 2015 - Google Patents
The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patientsHuang et al., 2015
View PDF- Document ID
- 15072918770332660359
- Author
- Huang J
- Yeh M
- Yu M
- Dai C
- Huang C
- Huang C
- Tsai P
- Lin P
- Chen Y
- Chang W
- Hou N
- Lin Z
- Chen S
- Chuang W
- Publication year
- Publication venue
- Journal of gastroenterology and hepatology
External Links
Snippet
Abstract Background and Aim: Pegylated interferon‐alpha plus ribavirin combination (PegIFN/RBV) therapy possesses positive effect in the secondary prevention of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients. The current study …
- 206010073071 Hepatocellular carcinoma 0 title abstract description 122
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miyaki et al. | Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients | |
| Wranke et al. | Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta | |
| Machado et al. | Hepatic steatosis in hepatitis B virus infected patients: meta‐analysis of risk factors and comparison with hepatitis C infected patients | |
| Bureau et al. | Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease | |
| Fang et al. | HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study | |
| Chen et al. | Predictors of alpha‐fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a–ribavirin combination therapy | |
| Giannini et al. | Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals | |
| D'Ambrosio et al. | Should surveillance for liver cancer be modified in hepatitis C patients after treatment‐related cirrhosis regression? | |
| Huang et al. | The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients | |
| Akuta et al. | Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older | |
| Matsumoto et al. | Factors associated with the effect of interferon‐α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B | |
| Wang et al. | Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir | |
| Fung et al. | Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case–control study | |
| Minami et al. | Comparison of improved prognosis between hepatitis B‐and hepatitis C‐related hepatocellular carcinoma | |
| Yasui et al. | Infectious complications, steroid use and timing for emergency liver transplantation in acute liver failure: analysis in a Japanese center | |
| Huang et al. | Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection | |
| Wahid et al. | Prevalence of thyroid stimulating hormone dysfunction among sofosbuvir‐treated HCV‐infected patients: A real‐world clinical experience | |
| Davidov-Derevynko et al. | The liver in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection | |
| Yeh et al. | Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy | |
| Satsangi et al. | Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C | |
| Huang et al. | Pegylated interferon plus ribavirin therapy improves pancreatic β‐cell function in chronic hepatitis C patients | |
| Khairy et al. | Serum MicroRNAs as predictors for fibrosis progression and response to direct‐acting antivirals treatment in hepatitis C virus genotype‐4 Egyptian patients | |
| Nayak et al. | Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases | |
| Hu et al. | Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of US veterans | |
| Xu et al. | Baseline hepatitis B virus DNA level is a promising factor for predicting the 3rd month virological response to entecavir therapy: a study of strict defined hepatitis B virus induced cirrhosis |